ABSTRACT
People recovered from COVID-19 may still present complications including respiratory and neurological sequelae. In other viral infections, cognitive impairment occurs due to brain damage or dysfunction caused by vascular lesions and inflammatory processes. Persistent cognitive impairment compromises daily activities and psychosocial adaptation. Some level of neurological and psychiatric consequences were expected and described in severe cases of COVID-19. However, it is debatable whether neuropsychiatric complications are related to COVID-19 or to unfoldings from a severe infection. Nevertheless, the majority of cases recorded worldwide were mild to moderate self-limited illness in non-hospitalized people. Thus, it is important to understand what are the implications of mild COVID-19, which is the largest and understudied pool of COVID-19 cases. We aimed to investigate adults at least four months after recovering from mild COVID-19, which were assessed by neuropsychological, ocular and neurological tests, immune markers assay, and by structural MRI and 18FDG-PET neuroimaging to shed light on putative brain changes and clinical correlations. In approximately one-quarter of mild-COVID-19 individuals, we detected a specific visuoconstructive deficit, which was associated with changes in molecular and structural brain imaging, and correlated with upregulation of peripheral immune markers. Our findings provide evidence of neuroinflammatory burden causing cognitive deficit, in an already large and growing fraction of the world population. While living with a multitude of mild COVID-19 cases, action is required for a more comprehensive assessment and follow-up of the cognitive impairment, allowing to better understand symptom persistence and the necessity of rehabilitation of the affected individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Coordenacao de Aperfeiçoamento de Pessoal de Nivel Superior - CAPES (processo 88881.504749/2020-01. 9951-Programa Estrategico Emergencial de Prevençao e Combate a Surtos. Endemias. Epidemias e Pandemias Edital de Seleção Emergencial I - Prevençao e Combate a Surtos. Endemias. Epidemias e Pandemias). Brazil; DMM, MARS, LADM, DMMQ, GB and WM are research fellows of the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)-Brazil, FAPEMIG (APQ-00735-19), INOVA Fiocruz. The authors thank CDTN (agreement number 23072.047899/2018-13) for providing 18F-FDG doses; and Hospital Risoleta Tolentino Neves and Hospital Odilon Behrens.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The recruitment of participants was approved by the Institutional Review Board of Universidade Federal de Minas Gerais (UFMG) (CAAE 3768820.1.0000.5149) and followed international ethical standards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
To protect the data privacy of the study participants, the dataset cannot be made publicly available. Specific data needed for reproducing results is available from the corresponding author upon reasonable request.
